Loading color scheme
ROCKVILLE, Md., Feb. 18, 2022 - OncoC4, Inc. is elated to announce that its co-founder and Chief Medical Officer, Dr. Pan Zheng, has been selected by the American Institute for Medical and Biological Engineering (AIMBE) to its 2022 College of Fellows.
ROCKVILLE, Md., Nov. 09, 2021 -- OncoC4, Inc., a clinical stage biopharma company focusing on immuno-oncology of cancer, reports a summary of preliminary clinical data from the ongoing Phase Ia clinical trial (PRESERVE-001, NCT04140526) evaluating the safety, tolerability and clinical activity of ONC-392 in cancer patients. ONC-392 is the only clinically tested nextgen anti-CTLA-4 monoclonal antibody that through a unique mechanism recycles, instead of destroys, the CTLA-4 molecules thereby reducing immunotherapy-related toxicity induced by the CTLA-4 depletion while enhancing therapeutic activities.
SHANGHAI and ROCKVILLE, Md., May 26, 2021 -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and OncoC4, Inc., a privately-held, clinical-stage biopharmaceutical company, today announced that the companies have entered into an exclusive contract development and manufacturing partnership for OncoC4's full pipeline of biologics including its late-stage project, ONC-392, a next generation CTLA-4 antibody which is under phase I clinical trials in the U.S. and China.
KENILWORTH, N.J., & ROCKVILLE, Md.--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and OncoImmune, a privately-held, clinical-stage biopharmaceutical company, today announced that the companies have entered into a definitive agreement pursuant to which Merck, through a subsidiary, will acquire all outstanding shares of OncoImmune for an upfront payment of $425 million in cash. In addition, OncoImmune shareholders will be eligible to receive sales-based payments and payments contingent on the successful achievement of certain regulatory milestones. OncoImmune recently announced positive top-line findings from an interim efficacy analysis of a Phase 3 study evaluating its lead therapeutic candidate CD24Fc for the treatment of patients with severe and critical COVID-19.
OncoImmune, Inc. announced today that it has dosed the first patient in the first-in-human clinical trial of ONC-392, its novel, next generation anti-CTLA-4 antibody, at the University of California (UC) Davis Comprehensive Cancer Center on September 16, 2020.
OncoImmune, Inc. announced today that its Investigational New Drug (“IND”) application for ONC-392, its novel, next generation anti-CTLA-4 antibody, has been approved by the U.S. Food and Drug Administration (“FDA”). The IND approval enables OncoImmune to begin a Phase 1A/1B clinical trial of ONC-392 that is designed to assess the safety, pharmacokinetics, and efficacy of ONC-392 as a single agent in advanced solid tumors and in combination with anti-PD(L)1 standard of care in Non- Small Cell Lung Cancer. This open label trial is expected to begin in early 2020.